Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants

Journal of Biological Chemistry

Volumn 288, Issue 23, 2013, Pages 16895-16904

  Fan, Ying Xin ^a   Wong, Lily ^a   Marino, Michael P ^b   Ou, Wu ^b   Shen, Yi ^a   Wu, Wen Jin ^a   Wong, Kwok Kin ^c   Reiser, Jakob ^b   Johnson, Gibbes R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL TRANSFORMATION; DOMINANT NEGATIVE; KINETIC ANALYSIS; PEPTIDE SUBSTRATES; PHOSPHORYLATION SITES; SUBSTRATE SELECTIVITY; TRANSFORMING ACTIVITY; TYROSINE RESIDUES;

AMINO ACIDS; BINDING ENERGY; BIOLOGICAL ORGANS; DISEASES; PEPTIDES; PHOSPHORYLATION; SUBSTRATES; TISSUE CULTURE;

ENZYMES;

BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN GAB1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; IN VITRO STUDY; LUNG CARCINOGENESIS; LUNG CARCINOMA; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADAPTOR PROTEINS; ENZYME MECHANISMS; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); ERBB2/HER2; GAB1; LUNG CANCER; ONCOGENIC MUTATION; TYROSINE-PROTEIN KINASE (TYROSINE KINASE);

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, TRANSGENIC; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

MUS MUSCULUS;

EID: 84878761974     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.434217     Document Type: Article

References (51)

1. Blume-Jensen, P., and Hunter, T. (2001) Oncogenic kinase signalling. Nature 411, 355-365 (Pubitemid 32467045)
2. Huse, M., and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275-282 (Pubitemid 34606870)
3. Lemmon, M. A., and Schlessinger, J. (2010) Cell signaling by receptor-tyrosine kinases. Cell 141, 1117-1134
4. Weinstein, I. B., and Joe, A. (2008) Oncogene addiction. Cancer Res. 68, 3077-3080
5. Citri, A., and Yarden, Y. (2006) EGF-ERBB signaling. Towards the systems level. Nat. Rev. Mol. Cell Biol. 7, 505-516 (Pubitemid 44036456)
6. Hynes, N. E., and Lane, H. A. (2005) ERBB receptors and cancer. The complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (Pubitemid 40637826)
7. Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., Fujisawa, T., Minna, J. D., and Gazdar, A. F. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65, 1642-1646 (Pubitemid 40478587)
8. Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., Barthorpe, A., Blow, M., Brackenbury, L., Butler, A., Clarke, O., Cole, J., Dicks, E., Dike, A., Drozd, A., Edwards, K., Forbes, S., Foster, R., Gray, K., Greenman, C., Halliday, K., Hills, K., Kosmidou, V., Lugg, R., Menzies, A., Perry, J., Petty, R., Raine, K., Ratford, L., Shepherd, R., Small, A., Stephens, Y., Tofts, C., Varian, J., West, S., Widaa, S., Yates, A., Brasseur, F., Cooper, C. S., Flanagan, A. M., Knowles, M., Leung, S. Y., Louis, D. N., Looijenga, L. H., Malkowicz, B., Pierotti, M. A., Teh, B., Chenevix-Trench, G., Weber, B. L., Yuen, S. T., Harris, G., Goldstraw, P., Nicholson, A. G., Futreal, P. A., Wooster, R., and Stratton, M. R. (2004) Lung cancer. Intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526
9. Fan, Y. X., Wong, L., Ding, J., Spiridonov, N. A., Johnson, R. C., and Johnson, G. R. (2008) Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J. Biol. Chem. 283, 1588-1596
10. Aertgeerts, K., Skene, R., Yano, J., Sang, B. C., Zou, H., Snell, G., Jennings, A., Iwamoto, K., Habuka, N., Hirokawa, A., Ishikawa, T., Tanaka, T., Miki, H., Ohta, Y., and Sogabe, S. (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2. J. Biol. Chem. 286, 18756-18765
11. Wang, S. E., Narasanna, A., Perez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G., Gazdar, A. F., Muthuswamy, S. K., and Arteaga, C. L. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10, 25-38
12. Perera, S. A., Li, D., Shimamura, T., Raso, M. G., Ji, H., Chen, L., Borgman, C. L., Zaghlul, S., Brandstetter, K. A., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Bronson, R. T., Shapiro, G. I., Greulich, H., Meyerson, M., Guertler, U., Chesa, P. G., Solca, F., Wistuba, I. I., and Wong, K. K. (2009) HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 474-479
13. Pawson, T., and Scott, J. D. (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278, 2075-2080 (Pubitemid 28028310)
14. Gu, H., and Neel, B. G. (2003) The "Gab" in signal transduction. Trends Cell Biol. 13, 122-130
15. Wöhrle, F. U., Daly, R. J., and Brummer, T. (2009) Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun. Signal 7, 22
16. Nishida, K., and Hirano, T. (2003) The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci. 94, 1029-1033 (Pubitemid 38035515)
17. Mattoon, D. R., Lamothe, B., Lax, I., and Schlessinger, J. (2004) The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol. 2, 24
18. Yamasaki, S., Nishida, K., Yoshida, Y., Itoh, M., Hibi, M., and Hirano, T. (2003) Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2. Oncogene 22, 1546-1556 (Pubitemid 36390604)
19. Itoh, M., Yoshida, Y., Nishida, K., Narimatsu, M., Hibi, M., and Hirano, T. (2000) Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol. Cell. Biol. 20, 3695-3704 (Pubitemid 30243915)
20. Deb, T. B., Wong, L., Salomon, D. S., Zhou, G., Dixon, J. E., Gutkind, J. S., Thompson, S. A., and Johnson, G. R. (1998) A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map but not c-Jun amino-terminal kinase activation. J. Biol. Chem. 273, 16643-16646 (Pubitemid 28311683)
21. Holgado-Madruga, M., Emlet, D. R., Moscatello, D. K., Godwin, A. K., and Wong, A. J. (1996) A Grb2-associated docking protein in EGF and insulin receptor signalling. Nature 379, 560-564 (Pubitemid 26049586)
22. Lehr, S., Kotzka, J., Herkner, A., Klein, E., Siethoff, C., Knebel, B., Noelle, V., Brüning, J. C., Klein, H. W., Meyer, H. E., Krone, W., and Müller-Wieland, D. (1999) Identification of tyrosine phosphorylation sites in human Gab-1 protein by EGF receptor kinase in vitro. Biochemistry 38, 151-159 (Pubitemid 29035681)
23. Fan, Y. X., Wong, L., Deb, T. B., and Johnson, G. R. (2004) Ligand regulates epidermal growth factor receptor kinase specificity. Activation increases preference for GAB1 and SHC versus autophosphorylation sites. J. Biol. Chem. 279, 38143-38150 (Pubitemid 39295960)
24. Pluta, K., Luce, M. J., Bao, L., Agha-Mohammadi, S., and Reiser, J. (2005) Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J. Gene Med. 7, 803-817 (Pubitemid 40872866)
25. Ou, W., Marino, M. P., Suzuki, A., Joshi, B. H., Husain, S. R., Maisner, A., Galanis, E., Puri, R., and Reiser, J. (2012) Specific targeting of human IL-13 receptor α2-positive cells with lentiviral vectors displaying IL-13. Hum. Gene. Ther. Methods 23, 137-147
26. Fan, Y. X., Wong, L., and Johnson, G. R. (2005) EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity. Biochem. J. 392, 417-423 (Pubitemid 43022719)
27. Cunnick, J. M., Dorsey, J. F., Munoz-Antonia, T., Mei, L., and Wu, J. (2000) Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor. J. Biol. Chem. 275, 13842-13848 (Pubitemid 30257458)
28. Cunnick, J. M., Mei, L., Doupnik, C. A., and Wu, J. (2001) Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J. Biol. Chem. 276, 24380-24387
29. Sithanandam, G., Smith, G. T., Fields, J. R., Fornwald, L. W., and Anderson, L. M. (2005) Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells. ErbB3 versus Gab1. Am. J. Respir. Cell Mol. Biol. 33, 490-499 (Pubitemid 41572693)
30. Hoeben, A., Martin, D., Clement, P. M., Cools, J., and Gutkind, J. S. (2013) Role of Grb2-associated binder 1 (GAB1) in epidermal growth factor receptor (EGFR)-induced signaling in head and neck squamous cell carcinoma. Int. J. Cancer 132, 1042-1050
31. Felici, A., Giubellino, A., and Bottaro, D. P. (2010) Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells. J. Cell. Biochem. 111, 310-321
32. Mood, K., Saucier, C., Bong, Y. S., Lee, H. S., Park, M., and Daar, I. O. (2006) Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor. Mol. Biol. Cell 17, 3717-3728 (Pubitemid 44330860)
33. Mohd Sharial, M. S., Crown, J., and Hennessy, B. T. (2012) Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann. Oncol. 23, 3007-3016
34. Vu, T., and Claret, F. X. (2012) Trastuzumab. Updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62
35. Shattuck, D. L., Miller, J. K., Carraway, K. L., 3rd, and Sweeney, C. (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-1477 (Pubitemid 351346855)
36. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer. Inst. 93, 1852-1857 (Pubitemid 34048651)
37. Yart, A., Mayeux, P., and Raynal, P. (2003) Gab1, SHP-2 and other novel regulators of Ras. Targets for anticancer drug discovery? Curr. Cancer Drug Targets 3, 177-192 (Pubitemid 36565760)
38. Segatto, O., Lonardo, F., Pierce, J. H., Bottaro, D. P., and Di Fiore, P. P. (1990) The role of autophosphorylation in modulation of erbB-2 transforming function. New Biol. 2, 187-195 (Pubitemid 20210039)
39. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 (Pubitemid 43866200)
40. Qiu, C., Tarrant, M. K., Choi, S. H., Sathyamurthy, A., Bose, R., Banjade, S., Pal, A., Bornmann, W. G., Lemmon, M. A., Cole, P. A., and Leahy, D. J. (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16, 460-467 (Pubitemid 351324111)
41. Fan, Y. X., Ju, M., Zhou, J. M., and Tsou, C. L. (1996) Activation of chicken liver dihydrofolate reductase by urea and guanidine hydrochloride is accompanied by conformational change at the active site. Biochem. J. 315, 97-102 (Pubitemid 26113541)
42. Tsou, C. L. (1993) Conformational flexibility of enzyme active sites. Science 262, 380-381
43. Songyang, Z., Carraway, K. L., 3rd, Eck, M. J., Harrison, S. C., Feldman, R. A., Mohammadi, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., and Eng, C. (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373, 536-539
44. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., and Haber, D. A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (Pubitemid 38637993)
45. Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., and Meyerson, M. (2004) EGFR mutations in lung cancer. Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (Pubitemid 38720929)
46. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., and Varmus, H. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306-13311 (Pubitemid 39209661)
47. Sordella, R., Bell, D. W., Haber, D. A., and Settleman, J. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (Pubitemid 39100331)
48. Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M., and Eck, M. J. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 105, 2070-2075 (Pubitemid 351439466)
49. Qiu, C., Tarrant, M. K., Boronina, T., Longo, P. A., Kavran, J. M., Cole, R. N., Cole, P. A., and Leahy, D. J. (2009) in vitro enzymatic characterization of near full-length EGFR in activated and inhibited states. Biochemistry 48, 6624-6632
50. Greulich, H., Chen, T. H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., and Meyerson, M. (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313
51. Gazdar, A. F., Shigematsu, H., Herz, J., and Minna, J. D. (2004) Mutations and addiction to EGFR. The Achilles "heal" of lung cancers? Trends Mol. Med. 10, 481-486 (Pubitemid 39303620)